We are live on ! Find out more
BIOT

Biotech Acquisition Company Class A Ordinary Shares
BIOT

Delisted

BIOT was delisted on the 2nd of February, 2023.

Back to rankings

58 hedge funds and large institutions have $146M invested in Biotech Acquisition Company Class A Ordinary Shares in 2021 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 13 increasing their positions, 4 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

225% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 4

117% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 6

21% more capital invested

Capital invested by funds: $121M → $146M (+$25.8M)

14% more funds holding

Funds holding: 51 → 58 (+7)

Holders
58
Holders Change
+7
Holders Change %
+13.73%
% of All Funds
1.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
13
Increased
13
Reduced
4
Closed
6
Calls
$98K
Puts
–
Net Calls
+$98K
Net Calls Change
+$12K

Top Buyers

Rank Fund Capital Flow
1
SRCM
Sage Rock Capital Management
New York
+$5.56M
2
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$3.36M
3
SCM
Saba Capital Management
New York
+$3.05M
4
RCM
Rivernorth Capital Management
Florida
+$2.18M
5
Marshall Wace
Marshall Wace
United Kingdom
+$2.09M

Top Sellers

Rank Fund Capital Flow
1
KSCM
Kamunting Street Capital Management
Florida
-$3.07M
2
RIA
RP Investment Advisors
Ontario, Canada
-$1.2M
3
TI
Telemetry Investments
New York
-$1.01M
4
MSU
Mizuho Securities USA
New York
-$559K
5
EAM
Exos Asset Management
New York
-$242K
Name Holding Trade Value Shares
Change 		Change in
Stake
CCP
1
Corbin Capital Partners
New York
$9.04M – – –
SCM
2
Saba Capital Management
New York
$8.81M +$3.05M +315,057 +53%
Citadel Advisors
3
Citadel Advisors
Florida
$8.77M +$20.4K +2,108 +0.2%
PC
4
Periscope Capital
Ontario, Canada
$7.4M -$1.94K -200 -0%
LA
5
Linden Advisors
New York
$6.61M – – –
MI
6
MMCAP International
Cayman Islands
$5.84M – – –
PAMP
7
Polar Asset Management Partners
Ontario, Canada
$5.84M – – –
SRCM
8
Sage Rock Capital Management
New York
$5.59M +$5.56M +573,800 New
ACM
9
Atalaya Capital Management
New York
$5.42M – – –
D.E. Shaw & Co
10
D.E. Shaw & Co
New York
$5.16M +$3.36M +346,182 +189%
Blackstone Inc
11
Blackstone Inc
New York
$4.87M – – –
DCM
12
DG Capital Management
New York
$4.38M – – –
DKCM
13
Davidson Kempner Capital Management
New York
$4.38M +$554K +57,202 +15%
RCM
14
Radcliffe Capital Management
Pennsylvania
$3.95M – – –
FTCM
15
Fir Tree Capital Management
New York
$3.92M +$28.2K +2,905 +0.7%
Nomura Holdings
16
Nomura Holdings
Japan
$3.89M – – –
Hudson Bay Capital Management
17
Hudson Bay Capital Management
Connecticut
$3.8M – – –
Marshall Wace
18
Marshall Wace
United Kingdom
$3.08M +$2.09M +216,038 +216%
MP
19
Mangrove Partners
Connecticut
$2.92M – – –
SC
20
Sculptor Capital
New York
$2.92M – – –
ACA
21
Arena Capital Advisors
California
$2.92M +$1.96M +202,728 +208%
Deutsche Bank
22
Deutsche Bank
Germany
$2.44M – – –
CC
23
Centiva Capital
New York
$2.42M – – –
Goldman Sachs
24
Goldman Sachs
New York
$2.28M -$5.82K -600 -0.3%
RCM
25
Rivernorth Capital Management
Florida
$2.19M +$2.18M +224,998 New
1
2 3

BIOT Hedge Fund Activity: Q3 2021 in Review

58 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Biotech Acquisition Company Class A Ordinary Shares (BIOT) for Q3 2021, worth a combined $146M — up 21% from $121M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new BIOT positions and 6 closed out — a net gain of 7 holders — while 13 added to existing stakes and 4 trimmed.

The largest buyer was Sage Rock Capital Management, opening a new position worth an estimated $5.56M. The largest seller was Kamunting Street Capital Management, exiting entirely with an estimated $3.07M sold.

  • 58 institutional investors held Biotech Acquisition Company Class A Ordinary Shares (BIOT) as of Q3 2021, up from 51 in Q2 2021.
  • Funds reported $146M of Biotech Acquisition Company Class A Ordinary Shares stock for Q3 2021, up 21% quarter-over-quarter.
  • 13 funds opened new Biotech Acquisition Company Class A Ordinary Shares positions in Q3 2021 and 6 closed out, a net change of +7 holders.
  • The largest Biotech Acquisition Company Class A Ordinary Shares buyer in Q3 2021 was Sage Rock Capital Management, an estimated $5.56M added.
  • The largest Biotech Acquisition Company Class A Ordinary Shares seller in Q3 2021 was Kamunting Street Capital Management, an estimated $3.07M sold.

Based on aggregated 13F filings for Q3 2021.